Lupin names new chief corporate development officer
MUMBAI — Lupin is looking to a longtime pharmaceutical industry veteran to head its business development and global mergers and acquisitions functions. The company named Jim Loerop its chief corporate development officer Monday, charging him with integrating its business development, licensing and M&A teams to drive its business strategy.
Loerop has been in the industry for 27 years, joining Lupin from Alexion Pharmaceuticals, where he was SVP global business development. Previously, he has worked for GlaxoSmithKline and its Stiefel, as well as KV Pharmaceutical and Curatek Pharmaceuticals. He started his career at Solvay Pharmaceuticals as a sales representative.
“We are delighted to welcome Jim at a crucial time as we accelerate our transition into complex generics and specialty brand segments,” Lupin CEO Vinita Gupta said. “Jim’s rich experience in both branded and generic business will be invaluable in helping us navigate our business towards new growth opportunities.”
Perrigo gets tentative FDA nod for Acanya generic
SILVER SPRING, Md. — Perrigo has received tentative approval from the Food and Drug Administration for its generic of Acanya (clindamycin phosphate, 1.2%, and benzoyl peroxide, 2.5%), the company announced Monday. Perrigo has previously settled litigation with Valeant Pharmaceuticals North America and Dow Pharmaceuticals concerning the product.
The drug is indicated to treat acne vulgaris in patients ages 12 years and older. It had U.S. sales of roughly $57 million for the 12 months ended July 2017, Perrigo said.
"The [research and development] team continues its efforts to achieve regulatory approvals for important new products,” Perrigo EVP and president Rx pharmaceuticals John Wesolowski said. This tentative approval reflects our continued dedication to developing extended topical products for patients."
Pharmacy joins expanded roster of TelaCare offerings
FISHERS, Ind. — Telemedicine company TelaCare is expanding the access of specialty care its users have access to — including pharmacists. The company on Friday announced the addition of pharmacists consultations, as well as consultations with dentists, optometrists, dietitians, sports medicine and alternative medicine professionals, to its offerings.
“Many Americans are without access to quality care today, and now for the first time ever, patients seeking virtual care will have even greater access and more care options thanks to this unique specialty offering from TelaCare," CEO Larry Jones said. “Primary care physicians, behavioral counseling and now pharmacists, dentists, optometrists, dietitians, sports medicine and alternative medicine professionals are further integrated into the TelaCare system, supporting our approach to patient-centered health care and enabling members to benefit from a closed-loop continuum of care.”
TelaCare’s solutions include a smartphone and tablet app, as well as kiosks and web apps for computers. The company said the expansion was a move that would increase engagement and make it easier for patients to access health care.
"Adding these additional telemedicine services to our patients at no additional charge helps us to build upon our goal of offering a broad suite of solutions to our employer and health plan partners, all with a common goal of providing consumers with better access to high quality care at a lower cost," Jones said.